The Potential Role of PKC β in Diabetic Retinopathy and Macular Edema

Adamis, 1996, Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate, Arch Ophthalmol, 114, 66, 10.1001/archopht.1996.01100130062010 Aiello, 1999, Protein kinase C beta selective inhibitor LY333531 ameliorates abnormal retinal hemodynamics in patients with diabetes, Diabetes, 48, A19 Aiello, 1997, Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor, Diabetes, 46, 1473, 10.2337/diabetes.46.9.1473 Aiello, 1998, Diabetic retinopathy, Diabetes Care, 21, 143, 10.2337/diacare.21.1.143 Aiello, 1995, Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins, Proc Natl Acad Sci USA, 92, 10457, 10.1073/pnas.92.23.10457 American Diabetes Association, 1993, Diabetic retinopathy, Diabetes Care, 23, S73 Barouch, 2000, Integrin mediated neutrophil adhesion and retinal leukostasis in diabetes, Invest Ophthamol Vis Sci, 4, 1153 Bursell, 1999, Can protein kinase C inhibition and vitamin E prevent the development of diabetic vascular complications?, Diab Res Clin Pract, 45, 169, 10.1016/S0168-8227(99)00047-9 Bursell, 1996, Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy, Invest Ophthalmol Vis Sci, 37, 886 Cameron, 2002, Effects of protein kinase Cbeta inhibition on neurovascular dysfunction in diabetic rats, Diabetes Metab Res Rev, 18, 315, 10.1002/dmrr.307 Cogan, 1961, Retinal vascular patterns. IV. Diabetic retinopathy, Arch Ophthalmol, 66, 100, 10.1001/archopht.1961.00960010368014 Danis, 1998, Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531, Invest Ophthalmol Vis Sci, 39, 171 Demolle, 1999, Pharmacokinetics and safety of multiple oral doses of LY333531, a PKC beta inhibitor, in healthy subjects, Clin Pharmacol Ther, 65, 189, 10.1016/S0009-9236(99)80287-2 Demolle, 1998, LY333531 single escalating oral dose study in health volunteers, Diabetologia, 41, A354 Denis, 2002, Advanced glycation end-products induce apoptosis of bovine retinal pericytes in culture, Free Radic Biol Med, 33, 236, 10.1016/S0891-5849(02)00879-1 Ferris, 1984, Macular edema. A complication of diabetic retinopathy, Surv Ophthalmol, 28, 452, 10.1016/0039-6257(84)90227-3 Ferris, 1993, How effective are treatments for diabetic retinopathy?, JAMA, 269, 1290, 10.1001/jama.269.10.1290 Ferris, 1999, Treatment of diabetic retinopathy, N Engl J Med, 341, 667, 10.1056/NEJM199908263410907 Friedman, 1999, Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications, Diabetes Care, 22, B65 Giugliano, 1996, Oxidative stress and diabetic vascular complications, Diabetes Care, 19, 257, 10.2337/diacare.19.3.257 Inoguchi, 1992, Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats, Proc Natl Acad Sci USA, 89, 11059, 10.1073/pnas.89.22.11059 Ishii, 1996, Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor, Science, 272, 728, 10.1126/science.272.5262.728 Ishii, 1998, Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus, J Mol Med, 76, 21, 10.1007/s109-1998-8101-y Jirousek, 1996, S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno- 1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues, J Med Chem, 39, 2664, 10.1021/jm950588y Kamei, 2001, Therapeutic potential of PKC inhibitors in painful diabetic neuropathy, Expert Opin Investig Drugs, 10, 1653, 10.1517/13543784.10.9.1653 Klein, 1988, Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy, JAMA, 260, 2864, 10.1001/jama.260.19.2864 Kowluru, 2001, Diabetes-induced elevations in retinal oxidative stress, protein kinase C and nitric oxide are interrelated, Acta Diabetol, 38, 179, 10.1007/s592-001-8076-6 Koya, 2000, Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes, FASEB J, 14, 439, 10.1096/fasebj.14.3.439 Koya, 1998, Protein kinase C activation and the development of diabetic complications, Diabetes, 47, 859, 10.2337/diabetes.47.6.859 Leitges, 1996, Immunodeficiency in protein kinase cbeta-deficient mice, Science, 273, 788, 10.1126/science.273.5276.788 Miller, 1997, Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy, Diabetes Metab Rev, 13, 37, 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K Morgan, 1989, Atrophic creep of the retinal pigment epithelium after focal macular photocoagulation, Ophthalmology, 96, 96, 10.1016/S0161-6420(89)32924-1 Naruse, 2000, Protein kinase C and myocardial biology and function, Circ Res, 86, 1104, 10.1161/01.RES.86.11.1104 Nishizuka, 1992, Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C, Science, 258, 607, 10.1126/science.1411571 Ozaki, 2000, Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization, Am J Pathol, 156, 697, 10.1016/S0002-9440(10)64773-6 Patz, 1973, Macular edema—an overlooked complication of diabetic retinopathy, Trans Am Acad Ophthalmol Otolaryngol, 77, OP34 Robinson, 1996, Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy, Proc Natl Acad Sci USA, 93, 4851, 10.1073/pnas.93.10.4851 Rutledge, 1993, Sub-pigment epithelial membranes after photocoagulation for diabetic macular edema, Arch Ophthalmol, 111, 608, 10.1001/archopht.1993.01090050042025 Seo, 1999, Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor, Am J Pathol, 154, 1743, 10.1016/S0002-9440(10)65430-2 Shah, 1988, The evolution of argon laser photocoagulation scars in patients with the ocular histoplasmosis syndrome, Arch Ophthalmol, 106, 1533, 10.1001/archopht.1988.01060140701038 Shiba, 1993, Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation, Am J Physiol, 265, E783 Spranger, 2001, Loss of the antiangiogenic pigment epithelial derived factor in patients with angiogenic eye disease, Diabetes, 50, 2641, 10.2337/diabetes.50.12.2641 Suzuma, 2002, Characterization of protein kinase C beta isoforms action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization, Proc Natl Acad Sci USA, 99, 721, 10.1073/pnas.022644499 Wakasaki, 1997, Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy, Proc Natl Acad Sci USA, 94, 9320, 10.1073/pnas.94.17.9320 Way, 2000, Identification of PKC-isoform-specific biological actions using pharmacological approaches, Trends Pharmacol Sci, 21, 181, 10.1016/S0165-6147(00)01468-1 Way, 2001, Protein kinase C and the development of diabetic vascular complications, Diabet Med, 18, 945, 10.1046/j.0742-3071.2001.00638.x Ways, 2000, The role of protein kinase C in the development of the complications of diabetes, Vitam Horm, 60, 149, 10.1016/S0083-6729(00)60019-5 Xia, 1996, Characterization of vascular endothelial growth factors effect on the activation of protein kinase C, its isoforms, and endothelial cell growth, J Clin Invest, 98, 2018, 10.1172/JCI119006